Cargando…
Structure-Based and Molecular Modeling Studies for the Discovery of Cyclic Imides as Reversible Cruzain Inhibitors With Potent Anti-Trypanosoma cruzi Activity
Chagas disease causes ~10,000 deaths each year, mainly in Latin America, where it is endemic. The currently available chemotherapeutic agents are ineffective in the chronic stage of the disease, and the lack of pharmaceutical innovation for Chagas disease highlights the urgent need for the developme...
Autores principales: | Ferreira, Rafael A. A., Pauli, Ivani, Sampaio, Thiago S., de Souza, Mariana L., Ferreira, Leonardo L. G., Magalhães, Luma G., Rezende, Celso de O., Ferreira, Rafaela S., Krogh, Renata, Dias, Luiz C., Andricopulo, Adriano D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6886403/ https://www.ncbi.nlm.nih.gov/pubmed/31824926 http://dx.doi.org/10.3389/fchem.2019.00798 |
Ejemplares similares
-
Multiparameter Optimization of Trypanocidal Cruzain Inhibitors With In Vivo Activity and Favorable Pharmacokinetics
por: Pauli, Ivani, et al.
Publicado: (2022) -
Chemoinformatics Studies on a Series of Imidazoles as Cruzain Inhibitors
por: Medeiros, Alex R., et al.
Publicado: (2021) -
The Trypanosoma cruzi Protease Cruzain Mediates Immune Evasion
por: Doyle, Patricia S., et al.
Publicado: (2011) -
Quantitative Structure–Activity Relationships for Structurally Diverse Chemotypes Having Anti-Trypanosoma cruzi Activity
por: de Souza, Anacleto S., et al.
Publicado: (2019) -
Structure-Based Virtual Screening and In Vitro Evaluation of New Trypanosoma cruzi Cruzain Inhibitors
por: Herrera-Mayorga, Verónica, et al.
Publicado: (2019)